Afuco™ Anti-IL23A ADCC Therapeutic Antibody (Risankizumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody Risankizumab is a humanized monoclonal antibody that specifically binds to human IL-23A and can be potentially used in the treatment of Crohn's disease, psoriasis, psoriatic arthritis and asthma.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-620LC |
| Pricing | Inquiry |
| Host | Human |
| Target | IL23A |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | ELISA |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |